Skip to main content
. 2022 May 25;8(6):e09538. doi: 10.1016/j.heliyon.2022.e09538

Figure 3.

Figure 3

The survival curve of all patients with advanced HCC related to HBV who received lenvatinib and sintilimab treatment and lenvatinib monotherapy. Cumulative overall survival curves, in which the blue lines show the patients in the combined therapy group and the red lines show the patients in the lenvatinib monotherapy group.